COVID-19 treatments Paxlovid and Lagevrio (molnupiravir) available to eligible patients

Updated 03/27/2023

Update, 3/27/2023 – The Color Health telehealth service to receive oral antiviral medication is now available to children ages 12 – 17, with parental or adult caregiver consent.

Update, 2/3/2023 – On Feb. 2, 2023, the U.S. Food and Drug Administration issued new guidelines stating that it is not necessary to test positive for COVID-19 in order to qualify for oral antiviral medications, Paxlovid or Lagevrio (molnupiravir).

Available in Spanish

Currently there are several Test to Treat (T2T) locations in Oregon. See below for details on how to use the federal T2T locator tool to find a site closest to you.
Make a plan in the event you get COVID-19. Using this form can help.
Learn more about COVID-19 treatments here, including how to use telehealth options to receive COVID-19 treatments quickly, at no cost.

There are several effective treatments for COVID-19. Two of those treatments are Paxlovid and Lagevrio (molnupiravir), antiviral pills for non-hospitalized patients. They are available by prescription to eligible people infected with the COVID-19 virus who have conditions that put them at risk for severe illness.

Eligibility for Paxlovid and Lagevrio:

People with certain health conditions like chronic lung disease or cancer are at higher risk for hospitalization or death from COVID-19 infection, as are people older than 65. Conditions that increase risk for severe COVID-19 include, but are not limited to:

  • Type 1 or 2 diabetes
  • Depression or schizophrenia
  • Chronic lung or heart diseases, including moderate to severe asthma
  • Cancer
  • Dementia or other neurological conditions
  • Down syndrome
  • Cystic fibrosis
  • Obesity
  • Pregnancy
  • Age may be a factor that contributes to higher risk

Check out the full list of eligible conditions from the Centers for Disease Control and Prevention.

Both Paxlovid and Lagevrio must be taken within five days of symptom onset, and there are currently two ways to get a prescription:

  1. A health care provider prescribes them to you. Because these medications are only available at certain pharmacies, you can find the pharmacy closest to you that carries them by using this online locator tool. Type in your ZIP code, the distance range, then click on the drop-down menu “Locations to fill a prescription.” Currently, dozens of pharmacies in Oregon, located in most counties, carry Paxlovid and Lagevrio. Pharmacies should not ask for any fees associated with the medication, including dispensing fees.
  1. If you don’t have access to a health care provider who can quickly determine your eligibility and write a prescription, the new federal Test to Treat (T2T) program is another option.

    Here’s how it works:
  • Using the online locator tool, type in your ZIP code and use the drop-down menu for “Locations with testing, medical visits, and medication (Test to Treat).”
  • Find the site closest to you and call to make an appointment. For help in Spanish and more than 150 languages, call 800-232-0233.
  • After your COVID-19 infection is confirmed, a health care provider will determine if you are eligible for Paxlovid and Lagevrio (molnupiravir). This medical evaluation will be performed on site, either in person or by telephone or video call.
  • If you’re eligible, the provider will call your prescription into the pharmacy on site or one close by.

If you have health insurance the entire process is free, though some insurance policies will have a co-pay.

If you don’t have health insurance or a health care provider, or if you live far from any Test-to-Treat locations or can’t get an appointment within five days of symptom onset, use the Color Health telehealth service. Color Health offers online or telephone support to get COVID-19 antivirals to eligible people ages 12 and up within 24-48 hours, regardless of health insurance status, at no cost. The service is available every day, 8 a.m. to 8 p.m., in multiple languages. You must provide an Oregon address to use the service, and parental or adult caregiver consent is required for patients under age 18.